Skip to main content Skip to section navigation Skip to footer
OPKO Health, Inc. Corporate homepage OPKO Health, Inc. Corporate homepage
  • Company
    • About Us
    • Team
    • Partner With Us
    • Careers
    • Contact
  • Pipeline
  • Science & Technology
    • ModeX Platforms
    • Long-Acting Biologics & Peptides
    • Publications
  • Global Pharmaceuticals
    • Our Medicines
    • Global Operations
  • Investors
    • Investors Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Governance
Site Announcement

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release
Visit BioReference Health

Press Releases

Investors

  • Investors Overview
  • News / Events
    • News / Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Information
    • Company Profile
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Information
    • Financial Information Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Chart
    • Historical Data
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • News / Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 3, 2023 4:05 pm EDT
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results
Jul 25, 2023 4:05 pm EDT
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
Jun 28, 2023 11:30 am EDT
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
May 3, 2023 4:05 pm EDT
OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
Apr 25, 2023 4:05 pm EDT
OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
Mar 9, 2023 8:00 am EST
OPKO Health to Hold Virtual R&D Day on March 20, 2023
Mar 8, 2023 8:00 am EST
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
Feb 23, 2023 4:05 pm EST
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
Feb 16, 2023 11:41 am EST
OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
Jan 3, 2023 8:00 am EST
OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 55
  • Next Pagearrow_forward
rss_feed News RSS

Sign up to receive company updates straight to your inbox.

Sign Up for Email Alerts

4400 Biscayne Boulevard
Miami, FL 33137

305-575-4100 / contact@opko.com

©2026 OPKO Health, Inc. All Rights Reserved.
  • Privacy Policy
  • Terms Of Use
  • Sitemap
  • Accessibility Statement
  • Consent Preferences